At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 354 enrolled
Drug / intervention
Herpes zoster vaccine GSK1437173Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
In Brief
A Phase 3 clinical trial evaluating Herpes zoster vaccine GSK1437173A for Herpes Zoster. Completed, enrolled 354 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesEstonia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartMar 2013
Primary CompletionMay 2014
Study CompletionApr 2015
TodayJul 2026
First PostedDec 17, 2012
Enrollment StartMar 12, 2013
Primary CompletionMay 22, 2014
Study CompletionApr 8, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.5 years ago
Interventions
Herpes zoster vaccine GSK1437173Abiological
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.